clinical trial · NCT05803421
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company·phase3·completed·n = 2,749
Type 2 DiabetesObesityOverweight or ObesityOverweightCardiovascular DiseasesChronic Kidney DiseaseOrforglipronInsulin Glargine
brief summary
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
started
Apr 3, 2023
primary completion
Mar 16, 2026
completion
Mar 16, 2026
last updated
Apr 17, 2026
official title
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol